Current management of the complications of portal hypertension:: variceal bleeding and ascites

被引:54
作者
Dib, N
Oberti, F
Calès, P
机构
[1] Ctr Hosp Univ, Dept Gastroenterol Hepatol, F-49933 Angers 09, France
[2] Univ Angers, HIFIH Lab, Angers, France
关键词
D O I
10.1503/cmaj.051700
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Portal hypertension is one of the main consequences of cirrhosis. It results from a combination of increased intrahepatic vascular resistance and increased blood flow through the portal venous system. The condition leads to the formation of portosystemic collateral veins. Esophagogastric varices have the greatest clinical impact, with a risk of bleeding as high as 30% within 2 years of medium or large varices developing. Ascites, another important complication of advanced cirrhosis and severe portal hypertension, is sometimes refractory to treatment and is complicated by spontaneous bacterial peritonitis and hepatorenal syndrome. We describe the pathophysiology of portal hypertension and the current management of its complications, with emphasis on the prophylaxis and treatment of variceal bleeding and ascites.
引用
收藏
页码:1433 / 1443
页数:11
相关论文
共 153 条
[1]   Propranolol for the prevention of first esophageal variceal hemorrhage:: A lifetime commitment? [J].
Abraczinskas, DR ;
Ookubo, R ;
Grace, ND ;
Groszmann, RJ ;
Bosch, J ;
Garcia-Tsao, G ;
Richardson, CR ;
Matloff, DS ;
Rodés, J ;
Conn, HO .
HEPATOLOGY, 2001, 34 (06) :1096-1102
[2]   Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis [J].
Abraldes, JG ;
Tarantino, I ;
Turnes, J ;
Garcia-Pagan, JC ;
Rodés, J ;
Bosch, J .
HEPATOLOGY, 2003, 37 (04) :902-908
[3]  
Abraldes Juan G, 2005, Clin Liver Dis, V9, P685, DOI 10.1016/j.cld.2005.08.001
[4]   OCTREOTIDE PREVENTS POSTPRANDIAL SPLANCHNIC HYPEREMIA IN PATIENTS WITH PORTAL-HYPERTENSION [J].
ALBILLOS, A ;
ROSSI, I ;
IBORRA, J ;
LLEDO, JL ;
CALLEJA, JL ;
BARRIOS, C ;
GARCIA, P ;
ESCARTIN, P .
JOURNAL OF HEPATOLOGY, 1994, 21 (01) :88-94
[5]   Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide [J].
Angeli, P ;
Volpin, R ;
Gerunda, G ;
Craighero, R ;
Rone, P ;
Merenda, R ;
Amodio, P ;
Sticca, A ;
Caregaro, L ;
Maffei-Faccioli, A ;
Gatta, A .
HEPATOLOGY, 1999, 29 (06) :1690-1697
[6]   Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis [J].
Angelico, M ;
Carli, L ;
Piat, C ;
Gentile, S ;
Capocaccia, L .
GASTROENTEROLOGY, 1997, 113 (05) :1632-1639
[7]  
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[8]   Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management [J].
Arroyo, V ;
Colmenero, J .
JOURNAL OF HEPATOLOGY, 2003, 38 :S69-S89
[9]   Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial [J].
Avgerinos, A ;
Nevens, F ;
Raptis, S ;
Fevery, J ;
Armonis, A ;
Manolakopoulos, S ;
Poulianos, G ;
Tzathas, C ;
Katsaros, D ;
Soutos, D ;
Zacharopoulose, A ;
Adler, M ;
Bourgeois, N ;
Bac, DJ ;
VanBuuren, HR ;
Decruyenaere, J ;
Elewaut, A ;
Deman, M ;
Lepoutre, L ;
VanderSpek, P ;
Hautekeete, M ;
Reynaert, H ;
Buyse, M ;
Ritter, L ;
Burtin, B ;
Darcis, T ;
Ioannou, J ;
Natens, J ;
Natens, O .
LANCET, 1997, 350 (9090) :1495-1499
[10]   THE EFFECT OF SOMATOSTATIN AND OCTREOTIDE ON INTRAVASCULAR ESOPHAGEAL VARICEAL PRESSURE IN PATIENTS WITH CIRRHOSIS [J].
AVGERINOS, A ;
ARMONIS, A ;
REKOUMIS, G ;
MANOLAKOPOULOS, S ;
ARGIRAKIS, G ;
RAPTIS, S .
JOURNAL OF HEPATOLOGY, 1995, 22 (03) :379-380